AstraZeneca Closes Acquisition of Amolyt Pharma
15 Julio 2024 - 1:00AM
Amolyt Pharma, a global, clinical-stage biopharmaceutical company
specializing in developing therapeutic peptides for rare endocrine
and related diseases, today announced that its previously announced
acquisition by the global pharmaceutical company, AstraZeneca, has
closed.
The acquisition bolsters the Alexion,
AstraZeneca Rare Disease late-stage pipeline and expands on its
bone metabolism franchise with the notable addition of
eneboparatide (AZP-3601), a Phase III investigational therapeutic
peptide with a novel mechanism of action designed to meet key
therapeutic goals for hypoparathyroidism. In patients with
hypoparathyroidism, a deficiency in parathyroid hormone (PTH)
production results in significant dysregulation of calcium and
phosphate, which can lead to life-altering symptoms and
complications, including chronic kidney disease. This programme,
together with Amolyt’s talented team, expertise, and earlier
pipeline, will enable Alexion’s expansion into rare
endocrinology.
Under the terms of the definitive agreement,
AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares
for a total consideration of up to $1.05 billion, on a cash and
debt free basis. This includes $800 million upfront at deal
closing, plus the right for Amolyt Pharma’s shareholders to receive
an additional contingent payment of $250 million payable upon
achievement of a specified regulatory milestone.
About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology
company, is building on its team’s established expertise to deliver
life-changing treatments to patients suffering from rare endocrine
and related diseases. Its development portfolio includes
eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a
potential treatment for hypoparathyroidism, and AZP-3813, a peptide
growth hormone receptor antagonist for the potential treatment of
acromegaly. To learn more, visit https://amolytpharma.com/ or
follow us on Twitter and LinkedIn.
Amolyt Contact: Patrick LoustauChief Business
Officerploustau@amolyt.com
Media inquiries: Jordyn TemperatoLifeSci
Communicationsjtemperato@lifescicomms.com